Global partnerships Alphamab has established strategic collaborations with CSPC, ArriVent, Glenmark and Pathos, enabling co-development, manufacturing and commercialization opportunities beyond China. This network can be leveraged to expand market access and accelerate regional licensing deals for ADCs and bispecifics.

Expanded portfolio The company offers a differentiated pipeline including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, dual-payload ADCs and next-generation ADCs, with market-ready Envafolimab and a growing set of INDs and Phase 1/2 programs. This breadth supports cross-sell across oncology indications and partner-driven co-development.

Late-stage potential Envafolimab is market approved as a subcutaneous PD-(L)1 inhibitor, simplifying administration. Additional candidates like KN026, JSKN016 and JSKN021 advancing through IND/clinical stages present near-term collaboration and licensing milestones for commercial-ready assets in multiple geographies.

Strategic geography Public indications of licensing outside Mainland China, HK, Macau, and Taiwan (Pathos collaboration) and ongoing global development suggest opportunities for regional partners to accelerate market entry, particularly in HER2 and PD-(L)1 pathways across Asia-Pacific, Europe and beyond.

Invested leadership New CTO appointment signals a focus on advancing technology platforms and manufacturing capabilities, aligning with BD aims to scale partnerships, optimize development timelines and improve manufacturing efficiencies for complex ADC and bispecific programs.